Physician profile
Daniel Bascara
NPI 1154488237
$3,614.65
in general payments reported to CMS, 2019-2025
19 companies · $1,348 in 2025
The $1,348 reported for 2025 was more than what 89% of Child & Adolescent Psychiatry providers received nationally (typical 2025 total: $132).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $597 · 2020: $225 · 2021: $117 · 2022: $28.00 · 2023: $396 · 2024: $904 · 2025: $1,348.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,643 · Education: $5.17.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,642.54 |
| Education | $5.17 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Axsome Therapeutics, INC. | $443.28 | 2023-2025 | Auvelity, Sunosi |
| Lundbeck LLC | $420.74 | 2019-2022 | |
| Otsuka America Pharmaceutical, INC. | $406.11 | 2019-2025 | Rexulti |
| Supernus Pharmaceuticals, INC. | $384.65 | 2023-2025 | Qelbree, Qelbree |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $259.49 | 2025 | Caplyta |
| Janssen Pharmaceuticals, INC | $259.08 | 2023-2025 | Spravato |
| E.R. Squibb & Sons, L.L.C. | $197.81 | 2024-2025 | Cobenfy |
| Ironshore Pharmaceuticals INC. | $179.37 | 2023-2024 | Jornay Pm |
| Takeda Pharmaceuticals U.S.A., INC. | $174.64 | 2019-2025 | Trintellix |
| Collegium Pharmaceutical, INC. | $169.08 | 2025 | Jornay Pm |
| Alkermes, INC. | $168.20 | 2024-2025 | Aristada, Lybalvi |
| Corium, LLC | $162.17 | 2023-2025 | Azstarys |
| Sunovion Pharmaceuticals INC. | $143.33 | 2019-2020 | |
| Vanda Pharmaceuticals INC. | $101.88 | 2025 | Fanapt |
| Neos Therapeutics, Lp | $46.37 | 2023-2025 | Cotempla Xr-Odt, Adzenys Xr-Odt |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Owp Pharmaceuticals, INC. | $33.38 | 2023-2025 | Subvenite, Lamotrigine |
| Teva Pharmaceuticals USA, INC. | $28.14 | 2024 | Austedo Xr |
| Allergan, INC. | $23.41 | 2019-2020 | |
| Jazz Pharmaceuticals INC. | $13.52 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Bascara listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.